Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine the safety and efficacy of quetiapine
(Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia
complicated by coexistent parkinsonism, or patients with Parkinson's disease with dementia
[PDD] who have episodes of agitation or psychosis. The secondary aim is to determine the
safety and tolerability, particularly the influence on parkinsonism, of quetiapine when used
to treat psychosis and/or agitation in patients with dementia complicated by coexistent
parkinsonism.